1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65EC417494B686F3E652583DE0025E150
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/enhancing-msl-interactions-us-healthcare-practitioners?opendocument
18
19opendocument
203.85.143.239
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Medical Science Liaison

Enhancing MSL Interactions with US Healthcare Practitioners

ID: POP-302


Features:

3 Info Graphics

12 Data Graphics

100 Metrics

6 Narratives


Pages: 22


Published: 2019


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
As the role of Medical Science Liaisons (MSLs) continues to evolve in the US, pharmaceutical companies are increasingly relying on MSLs to have meaningful scientific interactions with Healthcare Practitioners (HCPs). Moreover, organizations are continually re-evaluating and updating their guidelines for scientific interactions between MSLs and Healthcare Practitioners (HCPs).

Best Practices, LLC conducted this benchmarking research to gather insights on current MSL practices for HCP interactions in the US. In particular, this report delivers benchmarks around proactive disease presentations, unsolicited requests on clinical data and off-label uses, and group HCP presentations. This report also delivers insights on the frequency, format, content and evaluators for recertification of medical science liaisons in the US.

Field medical team leadership in the US can refer to this research to compare their MSL interaction guidelines with current industry practices.

Industries Profiled:
Pharmaceutical; Biotech; Diagnostic; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Manufacturing; Consumer Products; Medical Device


Companies Profiled:
AbbVie; Stealth Biothreapeutics; Abbott Vascular; Sanofi; Bayer; EMD Serono; Janssen; Astellas; Allergan; Ferring Pharmaceuticals; Sanofi Genzyme; Sandoz; Alkermes; BioMarin; AcelRx


Study Snapshot

Best Practices, LLC engaged 15 US medical affairs leaders from 15 leading biopharmaceutical companies in this research through a benchmarking survey. Eighty-seven percent of the respondents serve at the Director level; 7% at Vice President and 7% serve as Heads.


Key topics covered in this report include:

  • MSL Interactions with US HCP Groups
  • MSL Involvement in Proactive Disease State Education
  • MSL Engagement with KOLs in Early Development Stage
  • Best Practices for MSL Interactions
  • Re-certification of MSLs


Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Proactive Disease State Education: Study participants indicated their MSLs typically present proactive disease state education prior to launch, with six months before launch the most common period; however, 40% said their MSLs have no restrictions on the timing of the presentations.

  • Engaging KOLs: Eighty percent of respondents have their MSLs actively engaging KOLs before launch year. The most common period in the development process is post-Phase II results (33%).

Table of Contents

1.
Executive Summarypgs. 3-7
Benchmark Class
MSL Interactions Overview
2.
MSL Interactions with US HCPspgs. 8-13
3.
MSL Involvement in Proactive Disease State Educationpg. 14
4.
MSL Engagement with KOLs in Early Development Stagepg. 15
5.
Best Practices for MSL Interactionspg. 16
6.
Recertification of MSLspgs. 17-18
Format for Testing
Subject Matter/ Content for Testing
Evaluators for Recertification Testing
7.
Appendixpgs. 19-21

    List of Charts & Exhibits

    I. MSL Interactions with US HCPs

    • Permission given to MSLs to present standard of care treatment information in proactive disease presentation
    • Permission given to MSLs to leave behind slides from a disease state presentation on an HCP’s request
    • Permission given to MSLs to present clinical data on an unapproved product upon receiving an unsolicited request
    • Permission given to MSLs to present off-label clinical information of an approved product in a group HCP setting, upon receiving an unsolicited request
    • Permission given to MSLs to respond to off-label questions during a presentation in a group HCP setting
    • Development stage at which MSLs are allowed to do proactive disease state (non-product) education
    • Timing of MSL engagement of KOLs in the development process
    • Best practices for MSL interactions with HCPs

    II. MSL Recertification

    • Frequency, format, content and evaluators for recertification testing of MSLs